Fernando Noriega

6.0k total citations
69 papers, 2.4k citations indexed

About

Fernando Noriega is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health and Endocrinology. According to data from OpenAlex, Fernando Noriega has authored 69 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Infectious Diseases, 26 papers in Public Health, Environmental and Occupational Health and 23 papers in Endocrinology. Recurrent topics in Fernando Noriega's work include Mosquito-borne diseases and control (25 papers), Viral gastroenteritis research and epidemiology (22 papers) and Malaria Research and Control (18 papers). Fernando Noriega is often cited by papers focused on Mosquito-borne diseases and control (25 papers), Viral gastroenteritis research and epidemiology (22 papers) and Malaria Research and Control (18 papers). Fernando Noriega collaborates with scholars based in United States, France and Mexico. Fernando Noriega's co-authors include Myron M. Levine, James P. Nataro, Marcelo B. Sztein, David R. Maneval, Fang Liao, Alessio Fasano, John R. Czeczulin, Ian R. Henderson, Carlos Eslava and G Losonsky and has published in prestigious journals such as Journal of Clinical Investigation, PLoS ONE and PEDIATRICS.

In The Last Decade

Fernando Noriega

65 papers receiving 2.3k citations

Peers

Countries citing papers authored by Fernando Noriega

Since Specialization

Citations

This map shows the geographic impact of Fernando Noriega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Noriega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Noriega more than expected).

Fields of papers citing papers by Fernando Noriega

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Noriega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Noriega. The network helps show where Fernando Noriega may publish in the future.

Co-authorship network of co-authors of Fernando Noriega

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Noriega. A scholar is included among the top collaborators of Fernando Noriega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Noriega. Fernando Noriega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study 2025 ·The Lancet Infectious Diseases ·(unknown), Karen L. Kotloff, R. Scott McClelland, (unknown), Joyce S. Plested, Raj Kalkeri, MingZhu Zhu, (unknown), Zhaohui Cai, Katherine Clegg Smith, Mamadou Kaba, J C Nelson, (unknown), Raburn M. Mallory, Fernando Noriega, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	5
2	Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants–A randomized study 2023 ·PLoS ONE ·(unknown), (unknown), Satyajit Mohapatra, Sangappa Dhaded, (unknown), Sonali Kar, (unknown), (unknown), Jugesh Chhatwal, (unknown), Emmanuel Vidor, Annick Moureau, Dhaval M. Patel, (unknown), (unknown), (unknown), Fernando Noriega	1
3	Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study 2022 ·The Lancet Infectious Diseases ·(unknown), Juliana Park, Eduardo López‐Medina, María Rosario Capeding, (unknown), (unknown), (unknown), Maria Gonzales, Betzana Zambrano, Gustavo H. Dayan, (unknown), Hao Wang, Matthew Bonaparte, (unknown), (unknown), (unknown), Fernando Noriega	4
4	Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12–24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India 2022 ·Vaccine X ·(unknown), Sonali Palkar, Monjori Mitra, (unknown), (unknown), Annick Moureau, (unknown), (unknown), (unknown), (unknown), Emilia Jordanov, Fernando Noriega	1
5	A New Electrochemiluminescence-Based Multiplex Assay for the Assessment of Human Antibody Responses to Bordetella pertussis Vaccines 2021 ·Infectious Diseases and Therapy ·(unknown), (unknown), Lingyi Zheng, (unknown), (unknown), James W. Huleatt, (unknown), (unknown), Fernando Noriega, (unknown)	9
6	Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus 2020 ·Vaccine ·Gustavo H. Dayan, Edith Langevin, Rémi Forrat, Betzana Zambrano, Fernando Noriega, Carina Frago, Alain Bouckenooghe, Tifany Machabert, Stephen J. Savarino, Carlos A. DiazGranados	17
7	Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus 2020 ·Vaccine ·Gustavo H. Dayan, Edith Langevin, Peter B. Gilbert, Yukun Wu, Zoe Moodie, Rémi Forrat, Brenda Price, Carina Frago, Alain Bouckenooghe, Margarita Cortés, Fernando Noriega, Carlos A. DiazGranados	9
8	Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru 2016 ·The Pediatric Infectious Disease Journal ·Pío López, Claudio F. Lanata, Betzana Zambrano, Margarita Cortés, (unknown), (unknown), (unknown), (unknown), Héctor Verástegui, (unknown), Denis Crevat, (unknown), Fernando Noriega	20
9	Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America 2016 ·The Journal of Infectious Diseases ·(unknown), Laurent Coudeville, (unknown), Bruno Guy, Laurent Chambonneau, Fernando Noriega, Nicholas Jackson	42
10	Epidemiology of Clostridium difficile: a hospital-based descriptive study in Argentina and Mexico 2014 ·The Brazilian Journal of Infectious Diseases ·Gustavo Lopardo, Rayo Morfín‐Otero, (unknown), Fernando Noriega, Betzana Zambrano, Christine Luxemburger, Ginamarie Foglia, Enrique Rivas	22
11	Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: A randomized, controlled, open-label, multicenter study 2012 ·Vaccine ·Archana Chatterjee, (unknown), Meera Varman, Nicola P. Klein, (unknown), (unknown), Fernando Noriega	5
12	Safety and Immunogenicity Comparison of a Fourth Dose of DTaP-IPV//PRP-T (Pentacel™) to the Separate Administration of DAPTACEL ® and ActHIB ® 2005 ·Fernando Noriega	4
13	Effect of Pneumococcal Conjugate Vaccine (PCV-7) on Antibody Responses to Concomitantly Administered PENTACEL™ (DTaP-IPV//PRP-T) or Licensed Equivalent Vaccines 2005 ·Fernando Noriega	2
14	Safety and Immunogenicity of a Pentavalent Combination Vaccine (Diphtheria, Tetanus, Acellular Pertussis, Polio and Haemophilus Influenzae Type b Conjugate) When Administered as a Fourth Dose at 15 to 18 Months of Age 2005 ·Human Vaccines ·David W. Scheifele, Scott A. Halperin, Earl Rubin, Bruce Tapiéro, Roland Guasparini, William Meekison, Gerald Predy, Elaine L. Mills, Fernando Noriega	15
15	ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin 2000 ·Vaccine ·Richard J. Anderson, Marcela F. Pasetti, Marcelo B. Sztein, Myron M. Levine, Fernando Noriega	34
16	Attenuated ΔguaBA Salmonella typhi Vaccine Strain CVD 915 as a Live Vector Utilizing Prokaryotic or Eukaryotic Expression Systems to Deliver Foreign Antigens and Elicit Immune Responses 1999 ·Clinical Immunology ·Marcela F. Pasetti, Richard Anderson, Fernando Noriega, Myron M. Levine, Marcelo B. Sztein	53
17	Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo. 1997 ·Gut ·Alessio Fasano, Fernando Noriega, Fang Liao, (unknown), Myron M. Levine	62
18	Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. 1995 ·Journal of Clinical Investigation ·Alessio Fasano, Fernando Noriega, David R. Maneval, (unknown), Robert G. Russell, Stefano Guandalini, Myron M. Levine	111
19	Kinetics of the vibriocidal antibody response to live oral cholera vaccines 1994 ·Vaccine ·Steven S. Wasserman, Genevieve A. Losonsky, Fernando Noriega, Carol O. Tacket, Elizabeth Castañeda, Myron M. Levine	25
20	Vaccines to prevent enteric infections 1993 ·Baillière s Clinical Gastroenterology ·Myron M. Levine, Fernando Noriega	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact